BTK has emerged as a new molecular target for the treatment of B-lineage leukaemias and lymphomas, and Ibrutinib is the first BTK-specific inhibitor that entered the clinic, having been recently approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukaemia. The gene discussed is BTK; the disease is lymphoma.